MorphoSys: Hold Rating Until The Novartis Deal Closes

wildpixel A key update to the thesis: downgrading to a hold rating until the deal closes  As we predicted in our previous analysis, after phase 3 data of pelabresib, MorphoSys (NASDAQ:MOR) was acquired by Novartis on Feb 2024. MorphoSys's acquisition by Novartis for EUR 2.7 billion, or EUR68 per share. We believe this transaction not only showcases a significant premium over MorphoSys's pre-announcement share price but also underlines the strategic fit between the two companies, particularly in leveragi ...